Wikipedia

Protein kinase B

(Redirected from AKT)
"AKT" redirects here. For other uses, see AKT (disambiguation).

Protein kinase B (PKB), also known as Akt, is the collective name of a set of three serine/threonine-specific protein kinases that play key roles in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration.

AKT1
Ribbon Representation of crystal structure of Akt-1-inhibitor complexes.[1]
Identifiers
SymbolAKT1
NCBI gene207
HGNC391
OMIM164730
RefSeqNM_005163
UniProtP31749
Other data
LocusChr. 14 q32.32-32.33
Search for
StructuresSwiss-model
DomainsInterPro
AKT2
Crystal structure of Akt-2-inhibitor complexes.[2]
Identifiers
SymbolAKT2
NCBI gene208
HGNC392
OMIM164731
RefSeqNM_001626
UniProtP31751
Other data
LocusChr. 19 q13.1-13.2
Search for
StructuresSwiss-model
DomainsInterPro
AKT3
Identifiers
SymbolAKT3
NCBI gene10000
HGNC393
OMIM611223
RefSeqNM_181690
UniProtQ9Y243
Other data
LocusChr. 1 q43-44
Search for
StructuresSwiss-model
DomainsInterPro

Family members - Isoforms

edit

There are three different genes that encode isoforms of protein kinase B. These three genes are referred to as AKT1, AKT2, and AKT3 and encode the RAC alpha, beta, and gamma serine/threonine protein kinases respectively. The terms PKB and Akt may refer to the products of all three genes collectively, but sometimes are used to refer to PKB alpha and Akt1 alone.[citation needed]

Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes. Akt1 is also able to induce protein synthesis pathways, and is therefore a key signaling protein in the cellular pathways that lead to skeletal muscle hypertrophy and general tissue growth. A mouse model with complete deletion of the Akt1 gene manifests growth retardation and increased spontaneous apoptosis in tissues such as testes and thymus.[3] Since it can block apoptosis and thereby promote cell survival, Akt1 has been implicated as a major factor in many types of cancer.[4] Akt1 is also a positive regulator of cell migration.[5] Akt1 was originally identified as the oncogene in the transforming retrovirus, AKT8.[6]

Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport. In a mouse which is null for Akt1 but normal for Akt2, glucose homeostasis is unperturbed, but the animals are smaller, consistent with a role for Akt1 in growth. In contrast, mice which do not have Akt2, but have normal Akt1, have mild growth deficiency and display a diabetic phenotype (insulin resistance), again consistent with the idea that Akt2 is more specific for the insulin receptor signaling pathway.[7] Akt2 promotes cell migration as well.[5] The role of Akt3 is less clear, though it appears to be predominantly expressed in the brain. It has been reported that mice lacking Akt3 have small brains.[8]

Akt isoforms are overexpressed in a variety of human tumors, and, at the genomic level, are amplified in gastric adenocarcinomas (Akt1), ovarian (Akt2), pancreatic (Akt2) and breast (Akt2) cancers.[9][10]

Name

edit

The name Akt does not refer to its function. The "Ak" in Akt refers to the AKR mouse strain that develops spontaneous thymic lymphomas. The "t" stands for 'thymoma'; the letter was added when a transforming retrovirus was isolated from the Ak mouse strain, which was termed "Akt-8". The authors state, "Stock A Strain k AKR mouse originally inbred in the laboratory of Dr. C. P. Rhoads by K. B. Rhoads at the Rockefeller Institute." When the oncogene encoded in this virus was discovered, it was termed v-Akt. Thus, the more recently identified human analogs were named accordingly.[11]

Regulation

edit

Akt1 is involved in the PI3K/AKT/mTOR pathway and other signaling pathways.[5]

Binding phospholipids

edit

The Akt proteins possess a protein domain known as a PH domain, or pleckstrin homology domain, named after pleckstrin, the protein in which it was first discovered. This domain binds to phosphoinositides with high affinity. In the case of the PH domain of the Akt proteins, it binds either PIP3 (phosphatidylinositol (3,4,5)-trisphosphate, PtdIns(3,4,5)P3) or PIP2 (phosphatidylinositol (3,4)-bisphosphate, PtdIns(3,4)P2).[12] This is useful for control of cellular signaling because the di-phosphorylated phosphoinositide PIP2 is only phosphorylated by the family of enzymes, PI 3-kinases (phosphoinositide 3-kinase or PI3-K), and only upon receipt of chemical messengers which tell the cell to begin the growth process. For example, PI 3-kinases may be activated by a G protein coupled receptor or receptor tyrosine kinase such as the insulin receptor. Once activated, PI 3-kinase phosphorylates PIP2 to form PIP3.

Phosphorylation

edit

Once correctly positioned at the membrane via binding of PIP3, Akt can then be phosphorylated by its activating kinases, phosphoinositide-dependent kinase-1 (PDPK1 at threonine 308 in Akt1 and threonine 309 in Akt2) and the mammalian target of rapamycin complex 2 (mTORC2 at serine 473 (Akt1) and 474 (Akt2)) which is found at high levels in the fed state,[13][14] first by mTORC2. mTORC2 therefore functionally acts as the long-sought PDK2 molecule, although other molecules, including integrin-linked kinase (ILK) and mitogen-activated protein kinase-activated protein kinase-2 (MAPKAPK2) can also serve as PDK2. Phosphorylation by mTORC2 stimulates the subsequent phosphorylation of Akt isoforms by PDPK1.

Activated Akt isoforms can then go on to activate or deactivate their myriad substrates (e.g. mTOR) via their kinase activity.

Besides being a downstream effector of PI 3-kinases, Akt isoforms can also be activated in a PI 3-kinase-independent manner.[15] ACK1 or TNK2, a non-receptor tyrosine kinase, phosphorylates Akt at its tyrosine 176 residue, leading to its activation in PI 3-kinase-independent manner.[15] Studies have suggested that cAMP-elevating agents could also activate Akt through protein kinase A (PKA) in the presence of insulin.[16]

O-GlcNAcylation

edit

Akt can be O-GlcNAcylated by OGT. O-GlcNAcylation of Akt is associated with a decrease in T308 phosphorylation.[17]

Ubiquitination

edit

Akt1 is normally phosphorylated at position T450 in the turn motif when Akt1 is translated. If Akt1 is not phosphorylated at this position, Akt1 does not fold in the right way. The T450-non-phosphorylated misfolded Akt1 is ubiquitinated and degraded by the proteasome. Akt1 is also phosphorylated at T308 and S473 during IGF-1 response, and the resulting polyphosphorylated Akt is ubiquitinated partly by E3 ligase NEDD4. Most of the ubiquitinated-phosphorylated-Akt1 is degraded by the proteasome, while a small amount of phosphorylated-Akt1 translocates to the nucleus in a ubiquitination-dependent way to phosphorylate its substrate. A cancer-derived mutant Akt1 (E17K) is more readily ubiquitinated and phosphorylated than the wild type Akt1. The ubiquitinated-phosphorylated-Akt1 (E17K) translocates more efficiently to the nucleus than the wild type Akt1. This mechanism may contribute to E17K-Akt1-induced cancer in humans.[18]

Lipid phosphatases and PIP3

edit

PI3K-dependent Akt1 activation can be regulated through the tumor suppressor PTEN, which works essentially as the opposite of PI3K mentioned above.[19] PTEN acts as a phosphatase to dephosphorylate PIP3 back to PIP2. This removes the membrane-localization factor from the Akt signaling pathway. Without this localization, the rate of Akt1 activation decreases significantly, as do all of the downstream pathways that depend on Akt1 for activation.

PIP3 can also be de-phosphorylated at the "5" position by the SHIP family of inositol phosphatases, SHIP1 and SHIP2. These poly-phosphate inositol phosphatases dephosphorylate PIP3 to form PIP2.

Protein phosphatases

edit

The phosphatases in the PHLPP family, PHLPP1 and PHLPP2 have been shown to directly de-phosphorylate, and therefore inactivate, distinct Akt isoforms. PHLPP2 dephosphorylates Akt1 and Akt3, whereas PHLPP1 is specific for Akt2 and Akt3.[citation needed]

Function

edit

The Akt kinases regulate cellular survival[20] and metabolism by binding and regulating many downstream effectors, e.g. Nuclear Factor-κB, Bcl-2 family proteins, master lysosomal regulator TFEB and murine double minute 2 (MDM2).

Cell survival

edit
 
Overview of signal transduction pathways involved in apoptosis.

Akt kinases can promote growth factor-mediated cell survival both directly and indirectly. BAD is a pro-apoptotic protein of the Bcl-2 family. Akt1 can phosphorylate BAD on Ser136,[21] which makes BAD dissociate from the Bcl-2/Bcl-X complex and lose the pro-apoptotic function.[22] Akt1 can also activate NF-κB via regulating IκB kinase (IKK), thus result in transcription of pro-survival genes.[23]

Cell cycle

edit

The Akt isoforms are known to play a role in the cell cycle. Under various circumstances, activation of Akt1 was shown to overcome cell cycle arrest in G1[24] and G2[25] phases. Moreover, activated Akt1 may enable proliferation and survival of cells that have sustained a potentially mutagenic impact and, therefore, may contribute to acquisition of mutations in other genes.

Metabolism

edit

Akt2 is required for the insulin-induced translocation of glucose transporter 4 (GLUT4) to the plasma membrane. Glycogen synthase kinase 3 (GSK-3) could be inhibited upon phosphorylation by Akt, which results in increase of glycogen synthesis. GSK3 is also involved in Wnt signaling cascade, so Akt might be also implicated in the Wnt pathway. Its role in HCV induced steatosis is unknown.[citation needed]

Lysosomal biogenesis and autophagy

edit

Akt1 regulates TFEB, a master controller of lysosomal biogenesis,[26] by direct phosphorylation at serine 467.[27] Phosphorylated TFEB is excluded from the nucleus and less active.[27] Pharmacological inhibition of Akt promotes nuclear translocation of TFEB, lysosomal biogenesis and autophagy.[27]

Angiogenesis

edit

Akt1 has also been implicated in angiogenesis and tumor development. Although deficiency of Akt1 in mice inhibited physiological angiogenesis, it enhanced pathological angiogenesis and tumor growth associated with matrix abnormalities in skin and blood vessels.[28][29]

Clinical relevance

edit

Akt proteins are associated with tumor cell survival, proliferation, and invasiveness. The activation of Akt is also one of the most frequent alterations observed in human cancer and tumor cells. Tumor cells that have constantly active Akt may depend on Akt for survival.[30] Therefore, understanding the Akt proteins and their pathways is important for the creation of better therapies to treat cancer and tumor cells. A mosaic-activating mutation (c. 49G→A, p.Glu17Lys) in Akt1 is associated with the Proteus Syndrome, which causes overgrowth of skin, connective tissue, brain and other tissues.[31]

Akt inhibitors

edit

Akt inhibitors may treat cancers such as neuroblastoma. Some Akt inhibitors have undergone clinical trials. In 2007 VQD-002 had a phase I trial.[32] In 2010 Perifosine reached phase II.[33] but it failed phase III in 2012.

Miltefosine is approved for leishmaniasis and under investigation for other indications including HIV.

Akt1 is now thought to be the "key" for cell entry by HSV-1 and HSV-2 (herpes virus: oral and genital, respectively). Intracellular calcium release by the cell allows for entry by the herpes virus; the virus activates Akt1, which in turn causes the release of calcium. Treating the cells with Akt inhibitors before virus exposure leads to a significantly lower rate of infection.[34]

MK-2206 reported phase 1 results for advanced solid tumors in 2011,[35] and subsequently has undergone numerous phase II studies for a wide variety of cancer types.[36]

In 2013 AZD5363 reported phase I results regarding solid tumors.[37] with a study of AZD5363 with olaparib reporting in 2016.[38]

Ipatasertib is in phase II trials for breast cancer.[39]

Decreased Akt isoforms can cause deleterious effects

edit

Akt isoform activation is associated with many malignancies; however, a research group from Massachusetts General Hospital and Harvard University unexpectedly observed a converse role for Akt and one of its downstream effector FOXOs in acute myeloid leukemia (AML). They claimed that low levels of Akt activity associated with elevated levels of FOXOs are required to maintain the function and immature state of leukemia-initiating cells (LICs). FOXOs are active, implying reduced Akt activity, in ~40% of AML patient samples regardless of genetic subtype; and either activation of Akt or compound deletion of FoxO1/3/4 reduced leukemic cell growth in a mouse model.[40]

Hyperactivation of Akt1 can cause deleterious effects

edit

Two studies show that Akt1 is involved in Juvenile Granulosa Cell tumors (JGCT). In-frame duplications in the pleckstrin-homology domain (PHD) of the protein were found in more than 60% of JGCTs occurring in girls under 15 years of age. The JGCTs without duplications carried point mutations affecting highly conserved residues. The mutated proteins carrying the duplications displayed a non-wild-type subcellular distribution, with a marked enrichment at the plasma membrane. This led to a striking degree of Akt1 activation demonstrated by a strong phosphorylation level and corroborated by reporter assays.[41]

Analysis by RNA-Seq pinpointed a series of differentially expressed genes, involved in cytokine and hormone signaling and cell division-related processes. Further analyses pointed to a possible dedifferentiation process and suggested that most of the transcriptomic dysregulations might be mediated by a limited set of transcription factors perturbed by Akt1 activation. These results incriminate somatic mutations of Akt1 as major probably driver events in the pathogenesis of JGCTs.[42]

See also

edit

References

edit
  1. ^ PDB: 3MV5​; Freeman-Cook KD, Autry C, Borzillo G, Gordon D, Barbacci-Tobin E, Bernardo V, et al. (June 2010). "Design of selective, ATP-competitive inhibitors of Akt". Journal of Medicinal Chemistry. 53 (12): 4615–22. doi:10.1021/jm1003842. PMID 20481595.
  2. ^ PDB: 3D0E​; Heerding DA, Rhodes N, Leber JD, Clark TJ, Keenan RM, Lafrance LV, et al. (September 2008). "Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase". Journal of Medicinal Chemistry. 51 (18): 5663–79. doi:10.1021/jm8004527. PMID 18800763.
  3. ^ Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, et al. (September 2001). "Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene". Genes & Development. 15 (17): 2203–8. doi:10.1101/gad.913901. PMC 312770. PMID 11544177.
  4. ^ Nitulescu GM, Van De Venter M, Nitulescu G, Ungurianu A, Juzenas P, Peng Q, et al. (December 2018). "The Akt pathway in oncology therapy and beyond (Review)". International Journal of Oncology. 53 (6): 2319–2331. doi:10.3892/ijo.2018.4597. PMC 6203150. PMID 30334567.
  5. ^ a b c Pal DS, Banerjee T, Lin Y, de Trogoff F, Borleis J, Iglesias PA, et al. (July 2023). "Actuation of single downstream nodes in growth factor network steers immune cell migration". Developmental Cell. 58 (13): 1170–1188.e7. doi:10.1016/j.devcel.2023.04.019. PMC 10524337. PMID 37220748.
  6. ^ Staal SP, Hartley JW, Rowe WP (July 1977). "Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma". Proceedings of the National Academy of Sciences of the United States of America. 74 (7): 3065–7. Bibcode:1977PNAS...74.3065S. doi:10.1073/pnas.74.7.3065. PMC 431413. PMID 197531.
  7. ^ Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, et al. (July 2003). "Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta". The Journal of Clinical Investigation. 112 (2): 197–208. doi:10.1172/JCI16885. PMC 164287. PMID 12843127.
  8. ^ Yang ZZ, Tschopp O, Baudry A, Dümmler B, Hynx D, Hemmings BA (April 2004). "Physiological functions of protein kinase B/Akt". Biochemical Society Transactions. 32 (Pt 2): 350–4. doi:10.1042/BST0320350. PMID 15046607.
  9. ^ Hill MM, Hemmings BA (2002). "Inhibition of protein kinase B/Akt. implications for cancer therapy". Pharmacology & Therapeutics. 93 (2–3): 243–51. doi:10.1016/S0163-7258(02)00193-6. PMID 12191616.
  10. ^ Mitsiades CS, Mitsiades N, Koutsilieris M (May 2004). "The Akt pathway: molecular targets for anti-cancer drug development". Current Cancer Drug Targets. 4 (3): 235–56. doi:10.2174/1568009043333032. PMID 15134532.
  11. ^ Xie J, Weiskirchen R (2020). "What Does the "AKT" Stand for in the Name "AKT Kinase"? Some Historical Comments". Frontiers in Oncology. 10: 1329. doi:10.3389/fonc.2020.01329. PMC 7431881. PMID 32850422.
  12. ^ Franke TF, Kaplan DR, Cantley LC, Toker A (January 1997). "Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate". Science. 275 (5300): 665–8. doi:10.1126/science.275.5300.665. PMID 9005852. S2CID 31186873.
  13. ^ Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (February 2005). "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex". Science. 307 (5712): 1098–101. Bibcode:2005Sci...307.1098S. doi:10.1126/science.1106148. PMID 15718470. S2CID 45837814.
  14. ^ Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. (October 2006). "SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity". Cell. 127 (1): 125–37. doi:10.1016/j.cell.2006.08.033. PMID 16962653. S2CID 230319.
  15. ^ a b Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, et al. (March 2010). "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation". PLOS ONE. 5 (3): e9646. Bibcode:2010PLoSO...5.9646M. doi:10.1371/journal.pone.0009646. PMC 2841635. PMID 20333297.
  16. ^ Stuenaes JT, Bolling A, Ingvaldsen A, Rommundstad C, Sudar E, Lin FC, et al. (May 2010). "Beta-adrenoceptor stimulation potentiates insulin-stimulated PKB phosphorylation in rat cardiomyocytes via cAMP and PKA". British Journal of Pharmacology. 160 (1): 116–29. doi:10.1111/j.1476-5381.2010.00677.x. PMC 2860212. PMID 20412069.
  17. ^ Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, So WV, et al. (February 2008). "Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance". Nature. 451 (7181): 964–9. Bibcode:2008Natur.451..964Y. doi:10.1038/nature06668. PMID 18288188. S2CID 18459576.
  18. ^ Fan CD, Lum MA, Xu C, Black JD, Wang X (January 2013). "Ubiquitin-dependent regulation of phospho-AKT dynamics by the ubiquitin E3 ligase, NEDD4-1, in the insulin-like growth factor-1 response". The Journal of Biological Chemistry. 288 (3): 1674–84. doi:10.1074/jbc.M112.416339. PMC 3548477. PMID 23195959.
  19. ^ Cooper GM (2000). "Figure 15.37: PTEN and PI3K". The cell: a molecular approach. Washington, D.C.: ASM Press. ISBN 978-0-87893-106-4.
  20. ^ Song G, Ouyang G, Bao S (2005). "The activation of Akt/PKB signaling pathway and cell survival". Journal of Cellular and Molecular Medicine. 9 (1): 59–71. doi:10.1111/j.1582-4934.2005.tb00337.x. PMC 6741304. PMID 15784165.
  21. ^ Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2002). "Figure 15-60: BAD phosphorylation by Akt". Molecular biology of the cell. New York: Garland Science. ISBN 978-0-8153-3218-3.
  22. ^ Lodish H, Berk A, Zipursky LS, Matsudaira P, Baltimore D, Darnell J (1999). "Figure 23-50: BAD interaction with Bcl-2". Molecular cell biology. New York: Scientific American Books. ISBN 978-0-7167-3136-8.
  23. ^ Faissner A, Heck N, Dobbertin A, Garwood J (2006). "DSD-1-Proteoglycan/Phosphacan and Receptor Protein Tyrosine Phosphatase-Beta Isoforms during Development and Regeneration of Neural Tissues". Brain Repair. Advances in Experimental Medicine and Biology. Vol. 557. pp. 25–53, Figure 2: regulation of NF–κB. doi:10.1007/0-387-30128-3_3. ISBN 978-0-306-47859-8. PMID 16955703.
  24. ^ Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, et al. (March 1999). "Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway". Proceedings of the National Academy of Sciences of the United States of America. 96 (5): 2110–5. Bibcode:1999PNAS...96.2110R. doi:10.1073/pnas.96.5.2110. PMC 26745. PMID 10051603.
  25. ^ Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, et al. (November 2002). "Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage". Molecular and Cellular Biology. 22 (22): 7831–41. doi:10.1128/MCB.22.22.7831-7841.2002. PMC 134727. PMID 12391152.
  26. ^ Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, et al. (July 2009). "A gene network regulating lysosomal biogenesis and function". Science. 325 (5939): 473–7. Bibcode:2009Sci...325..473S. doi:10.1126/science.1174447. PMID 19556463. S2CID 20353685.
  27. ^ a b c Palmieri M, Pal R, Nelvagal HR, Lotfi P, Stinnett GR, Seymour ML, et al. (February 2017). "mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases". Nature Communications. 8: 14338. Bibcode:2017NatCo...814338P. doi:10.1038/ncomms14338. PMC 5303831. PMID 28165011.
  28. ^ Chen J, Somanath PR, Razorenova O, Chen WS, Hay N, Bornstein P, et al. (November 2005). "Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo". Nature Medicine. 11 (11): 1188–96. doi:10.1038/nm1307. PMC 2277080. PMID 16227992.
  29. ^ Somanath PR, Razorenova OV, Chen J, Byzova TV (March 2006). "Akt1 in endothelial cell and angiogenesis". Cell Cycle. 5 (5): 512–8. doi:10.4161/cc.5.5.2538. PMC 1569947. PMID 16552185.
  30. ^ "Tumor Genetics; AKT Function and Oncogenic Activity" (PDF). Scientific Report. Fox Chase Cancer Center. 2005. Archived from the original (PDF) on 2010-06-04. Retrieved 2013-01-23.
  31. ^ Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, et al. (August 2011). "A mosaic activating mutation in AKT1 associated with the Proteus syndrome". The New England Journal of Medicine. 365 (7): 611–9. doi:10.1056/NEJMoa1104017. PMC 3170413. PMID 21793738.
  32. ^ "VioQuest Pharmaceuticals Announces Phase I/IIa Trial For Akt Inhibitor VQD-002". Apr 2007.
  33. ^ Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, et al. (February 2010). "Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia". Clinical Cancer Research. 16 (3): 1033–41. doi:10.1158/1078-0432.CCR-09-1837. PMC 2885252. PMID 20103671.
  34. ^ Cheshenko N, Trepanier JB, Stefanidou M, Buckley N, Gonzalez P, Jacobs W, et al. (July 2013). "HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression". FASEB Journal. 27 (7): 2584–99. doi:10.1096/fj.12-220285. PMC 3688744. PMID 23507869.
  35. ^ Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, et al. (December 2011). "First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors". Journal of Clinical Oncology. 29 (35): 4688–95. doi:10.1200/JCO.2011.35.5263. PMID 22025163.
  36. ^ MK-2206 phase-2 trials
  37. ^ AKT inhibitor AZD5363 well tolerated, yielded partial response in patients with advanced solid tumors
  38. ^ "PARP/AKT Inhibitor Combination Active in Multiple Tumor Types. April 2016". Archived from the original on 2016-05-07. Retrieved 2016-04-20.
  39. ^ Jabbarzadeh Kaboli P, Salimian F, Aghapour S, Xiang S, Zhao Q, Li M, et al. (June 2020). "Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy". Pharmacological Research. 156: 104806. doi:10.1016/j.phrs.2020.104806. PMID 32294525. S2CID 215793444.
  40. ^ Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, et al. (September 2011). "AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias". Cell. 146 (5): 697–708. doi:10.1016/j.cell.2011.07.032. PMC 3826540. PMID 21884932.
  41. ^ Bessière L, Todeschini AL, Auguste A, Sarnacki S, Flatters D, Legois B, et al. (May 2015). "A Hot-spot of In-frame Duplications Activates the Oncoprotein AKT1 in Juvenile Granulosa Cell Tumors". eBioMedicine. 2 (5): 421–31. doi:10.1016/j.ebiom.2015.03.002. PMC 4485906. PMID 26137586.
  42. ^ Auguste A, Bessière L, Todeschini AL, Caburet S, Sarnacki S, Prat J, et al. (December 2015). "Molecular analyses of juvenile granulosa cell tumors bearing AKT1 mutations provide insights into tumor biology and therapeutic leads". Human Molecular Genetics. 24 (23): 6687–98. doi:10.1093/hmg/ddv373. PMID 26362254.

Further reading

edit
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Protein_kinase_B&oldid=1241353475"